CurrentCentenePolicy CP PHAR.2OI

Belatacept (Nulojix) for kidney transplant rejection prophylaxis

This policy governs medical necessity criteria and prior authorization requirements for belatacept (Nulojix) when used for prophylaxis of organ rejection in adult kidney transplant recipients under Centene lines of business.

Policy Summary

PayerCentene

PolicyBelatacept (Nulojix) for kidney transplant rejection prophylaxis

Policy CodePolicy CP PHAR.2OI

Change TypeNo material changes

Effective Date03.01.16

Next Review Date

Key ActionProvider must submit documentation (e.g., office chart notes, lab results) demonstrating the member meets all approval criteria, including EBV seropositive status and transplant specialist involvement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsInitial approval duration

12 monthsContinued therapy duration

SeropositiveRequired EBV status

J0485HCPCS code

Coverage Criteria for Belatacept (Nulojix)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Use of belatacept (Nulojix) for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established. Requests for non–FDA approved indications that are not addressed in this policy may be denied unless the provider supplies sufficient documentation of efficacy and safety in accordance with applicable off‑label use policies.

Coverage and payment are governed by the member's benefit documents. Coverage is subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance) and applicable Health Plan administrative policies and procedures.

Coding and Dose Rules

HCPCS CodesHCPCS

J0485

Injection, belatacept, 1 mg

inv-07: Dose divisibility — Prescribed dose must be evenly divisible by 12.5 mg

Dose divisibility requirementPrescribed dose must be evenly divisible by 12.5 mg to allow accurate preparation from the reconstituted solution and provided syringe.

Source dosing contextRequirement referenced in the Dosage and Administration section for kidney transplant prophylaxis initial and maintenance phases.

RationaleEnsures accurate preparation and administration using vial reconstitution and syringe volumes.

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must submit documentation supporting that belatacept (Nulojix) is prescribed for kidney transplant rejection prophylaxis and that the request meets all approval criteria.

Affected drug: Belatacept (Nulojix)
Approval duration: 6 months
Required prescriber: Kidney transplant specialist or in consultation with one

Note

Prior Authorization Guidance

This policy is a guide to medical necessity to assist in coverage decisions and administering benefits. Coverage and administration are subject to all terms, conditions, exclusions, and limitations of the member's coverage documents and applicable law. Providers are expected to exercise professional medical judgment; this policy does not replace that judgment.

Documentation Required

Required Documentation

Provider must submit supporting documentation with the prior authorization request, such as office notes and relevant laboratory results (including EBV serostatus) demonstrating the member meets all approval criteria.

Required documentation: Office chart notes, transplant consultation, dosing schedule, concurrent immunosuppressive regimen, EBV serology results
Denial triggers: Requests for EBV seronegative or unknown EBV status; non‑FDA indications without off‑label supporting documentation

Note

Provider Responsibility / Professional Judgment

Providers are responsible for exercising professional medical judgment when treating members. This policy is informational and not a substitute for individualized clinical decision-making. Providers retain responsibility for clinical management, and for ensuring requests conform to plan requirements prior to submission.

Denial Risk

Non‑FDA Indications

Requests for non–FDA approved indications may be denied unless sufficient supporting documentation is provided per applicable off‑label use policies.

Denial Risk

EBV Seronegativity Contraindication

Belatacept is contraindicated in transplant recipients who are EBV seronegative or with unknown EBV serostatus due to risk of post‑transplant lymphoproliferative disorder. Requests for members with EBV seronegativity or unknown status may be denied.

Ensure EBV serostatus is documented prior to authorization request

Documentation and Evaluation Requirements

Documentation Required

Evaluation requirements: chart notes, labs, and response assessment

Submit evaluation documentation with authorization requests, including chart notes and laboratory results (for example, EBV serology) to demonstrate the member meets candidate and approval criteria; documentation of therapeutic response may be required for continued therapy.

Provide evidence of current receipt of Nulojix for ≥ 30 days for continued therapy requests.
Include documentation showing member is responding to therapy for continuation approvals.

Prior Authorization

Center requirements: specialist prescription or consultation required

Prescriptions must be written by or in consultation with a kidney transplant specialist, implying involvement of a transplant center for belatacept therapy.

Authorization requests should document the transplant specialist involved in care.

Post-Transplant Coverage / Maintenance Dosing

inv-23: Belatacept infusions (maintenance dosing every 4 weeks) — Continued therapy approvals granted for 12 months when member is responding and dosing limits maintained

Continued therapy approval durationContinued therapy approvals granted for 12 months when member is responding to therapy.

Maintenance dosing scheduleMaintenance dosing 5 mg/kg at end of week 16 and every 4 weeks (±3 days) thereafter; dosing limits must be maintained (≤5 mg/kg per infusion).

Response requirementMember must be responding positively to therapy for continued approval.

Dose increase constraintIf request is for a dose increase, the new dose must not exceed 5 mg/kg per infusion at maintenance intervals.

Definitions

inv-18: EBV — Epstein-Barr virus serostatus required positive prior to belatacept use due to PTLD risk

EBV serostatus requirementEpstein-Barr virus (EBV) serostatus must be positive prior to belatacept use due to risk of post-transplant lymphoproliferative disorder (PTLD).

ContraindicationUse is contraindicated in transplant recipients who are EBV seronegative or have unknown EBV serostatus because of PTLD risk, predominantly involving the central nervous system.

AbbreviationEBV = Epstein-Barr virus.

Background

Belatacept is a selective T‑cell costimulation blocker indicated to prevent organ rejection in adult kidney transplant recipients. It is used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids per the FDA‑approved regimen. Use is limited to EBV seropositive patients due to the risk of post‑transplant lymphoproliferative disorder.